40results about How to "Trigger immune response" patented technology

The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.

The invention discloses a Chinese isolate of Leachiii mycoplasma, an isolation medium and purpose thereof. The Chinese isolate of Leachiii mycoplasma has a microbe preservation No. of CGMCC No.3808. The invention also discloses a medium suitable for isolation or subculturing of the Chinese isolate of Leachiii mycoplasma. Pathogenic test results show that inoculating subculture of Leachiii mycoplasma isolate of the invention in joint of 1-2 month healthy calf can replicate typical polyarthritis and cause certain death; the dead calf has obvious constitutional symptom and obvious pathological changes in multiple tissues and organs. According to clinical symptoms and pathological changes of clinical morbidity and artificial inoculated calf, epidemic features of the disease, tracking epidemiology investigation and singular PRC identification and genetic evolution analysis of isolated pathogeny, it is proved that the mycoplasma isolated by the invention is Leachiii mycoplasma.

The invention discloses lactobacillus plantarum capable of promoting the secretion of SIgA (Secretory Immunoglobulin A) in an intestinal canal. The lactobacillus plantarum is characterized by being separated from koumiss samples collected in China and is collected at China General Microbiological Culture Collection Center of Microbiological Culture Management Committee, the collection number is CGMCC No. 5468, and the collection date is 18th, November 2011. The invention also discloses a detecting method of the lactobacillus plantarum.

The invention relates to a novel bacillus subtilis multi-valent vector-based vaccine and application thereof. The novel bacillus subtilis multi-valent vector-based vaccine comprises a bacillus subtilis recombination strain obtained by using a genetic engineering method, wherein the bacillus subtilis recombination strain is classified and named as bacillus subtilis HT5302 and is preserved in the China Center For Type Culture Collection (CCTCC) with a preservation number of CCTCC No:M2012380. The novel bacillus subtilis multi-valent vector-based vaccine is prepared by using the bacillus subtilis recombination strain as a core. A spore with a surface having no a streptococcus agalactiae 3-glyceraldehyde-phosphate dehydrogenase (GAPDH) protein can be generated through inducing the bacillus subtilis recombination strain, and secretes a fusion protein which formed by cell-penetrating peptide and vibrio anguillarum 3-GAPDH when germinating to form a nutrient cell. The novel bacillus subtilis multi-valent vector-based vaccine has a multi-valent protection function on bacterial diseases such as streptococcicosis, vibriosis, edwardsienosis and aeromonas hydrophila.

The invention discloses an epitope based on IL-6 and application of the epitope and particularly provides epitope peptide. The epitope peptide is derived from mammal IL-6 and includes one or more epitopes. The length of the amino acid sequence of the epitope is 2-100% the whole length of the IL-6. The length of the epitope peptide is 3-300 amino acids. Besides, recombinant protein composed of the epitope peptide and carrier protein can induce immune response, to the IL-6, generated by mammals of the same time. The invention further provides fusion protein containing the epitope peptide. The recombinant protein prepared through fusion expression of the epitope peptide and the carrier protein is used and can effectively activate the immune response, to the IL-6, of an organism.

The invention belongs to the field of tumor biotherapy and relates to a tumor cell vaccine and a preparation method thereof. The technical problem to be solved by the invention is to provide an effective tumor prevention and cure vaccine. To solve the technical problem, the invention adopts a technical scheme of providing the tumor cell vaccine. The tumor cell vaccine uses tumor cells, which are inactivated and lose differentiating and proliferating capability, but can still express a vascular endothelium growth factor and contain vascular endothelium growth factor expression vectors, as main active ingredients.

The invention provides a preparation method and application of a bacillus cereus monoclonal antibody. The preparation method comprises the following steps of: 1, preparing bacterial antigen through fixation of bacillus cereus by incubation treatment of paraform; 2, injecting the bacterial antigen so as to avoid emulsification; 3, performing short spacing impulse injection so as to quickly promote immunization; 4, planting solid tumors so as to rejuvenate tumor cells; 5, performing chemical induction and fusion; 6, performing semifluid selection so as to obtain monoclonal hybridoma; 7, performing cooperation of negative screening and positive screening so as to obtain a specific antibody; and 8, using a polyclonal antibody as a capture antibody and using a monoclonal antibody as a detection antibody to establish dual-antibody sandwich ELISA.

The invention relates to the field of biotechnology, and the invention discloses a use of CCL5. The present invention utilizes the chemotactic binding ability of CCL5 and immune cell surface receptors such as DC cells to transport different antigenic proteins to the surface of DC cells, improves the efficiency of phagocytosis, processing and presentation of various antigenic proteins by DC cells, and improves the efficiency of DC cells. The effect of preventing and treating related diseases. The present invention also adds T2 sequence to the antigen so as to enhance the immune effect.

The invention discloses a veterinary antivirus composition, freeze-dried powder, a preparation method and applications of the composition, and belongs to the technical field of veterinary feed additive. The veterinary antivirus composition is mainly composed of the following components in parts by weight: 85 to 100 parts of veterinary antivirus yolk antibody, 1 to 5 parts of veterinary antivirus transfer factor, and 1 to 5 parts of alpha-interferon; and preferably also comprises the following components in parts by weight: 5 to 10 parts of astragalus polysaccharide, 5 to 10 parts of angelica polysaccharide, 10 to 20 parts of wolfberry polysaccharide, and 10 to 30 parts of licorice polysaccharide. The veterinary antivirus yolk antibody, veterinary antivirus transfer factor, alpha-interferon, astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide, and licorice polysaccharide are co-used, and thus the composition has the advantages of strong pertinency, high antibody titer, and good bio-activity, is capable of improving the organism immunity and disease preventing ability, and effectively prevents the animal viral diseases.

The invention discloses an antiviral composition for poultry, freeze-dried powder, a preparation method and application, and belongs to the technical field of feed additives for livestock and poultry. The antiviral composition for poultry is mainly composed of the following components in parts by weight: 90-100 parts of anti-viral yolk antibody for poultry, 1-2 parts of anti-viral transfer factor for poultry, and 1-2 parts of α-interferon; preferably It also includes the following components in parts by weight: 5-10 parts of astragalus polysaccharide, 5-10 parts of angelica polysaccharide, 10-20 parts of wolfberry polysaccharide, and 10-30 parts of licorice polysaccharide. In the present invention, antiviral egg yolk antibody for poultry, antiviral transfer factor for poultry, α-interferon and traditional Chinese medicine extracts astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide and licorice polysaccharide are compounded, which can effectively improve the immunity and disease resistance of poultry bodies Ability to prevent and control poultry viral diseases. After being prepared into freeze-dried powder, it can be stored at room temperature for a long time, and has high antibody titer and good biological activity.

The present invention discloses an FIX-based epitope and application thereof. In particular, the present invention provides an antigen peptide. The antigen peptide derive from animal FIX and comprises one or more epitopes. The length of an antigen peptide amino acid sequence is 2%-100% of the full length of the FIX, and the length of the antigen peptide is 5-500 amino acids; and recombinant protein formed by the antigen peptide and carrier protein can induce the animals of the same species to produce an immune response against the FIX. The fusion of the antigen peptide and the carrier protein can stimulate a strong humoral immune response, and produce specific antibodies against the FIX. The present invention further discloses specific identification, and a preparation method for FIX antibodies combined with human FIX antibodies. The antibodies prepared by the preparation method provided by the invention can be used for human FIX separation and purification, detection and treatment of diseases associated with epitopes.

The invention discloses preparation of a neutralizing monoclonal antibody of an anti-hepatitis C virus and application thereof. E2 protein is utilized to strengthen immunity after mice are immunized by pVAX-CpG-N2N8; spleen of the mice with the highest valence aiming at the E2 antibody is taken as an antigen-sensitized B cell and fused with a myeloma cell SP2 / 0 strain, and the fused cell is screened in HAT culture medium, so as to obtain the fused cell, and the fused grows and is cloned to obtain the hybridoma cell strain generating the monoclonal antibody disclosed by the invention. The neutralizing monoclonal antibody of the anti-hepatitis C virus E2 disclosed by the invention is generated by the hybridoma cell strain; epitope combined with the monoclonal antibody is at F550GCTWMNSTGFTKVCGAPPCVIG572 part of E2 glycoprotein. The neutralizing monoclonal antibody of the anti-hepatitis C virus disclosed by the invention has good capability of neutralizing HCV infection, can be used as a hepatitis C virus therapeutic antibody, and has a great application prospect in hepatitis C diagnosis and treatment.